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Aging is associated with a dysregulation of the immune response, loosely termed
“immunosenescence.” Each part of the immune system is influenced to some extent
by the aging process. However, adaptive immunity seems more extensively affected and
among all participating cells it is the T cells that are most altered. There is a large body
of experimental work devoted to the investigation of age-associated differences in T cell
phenotypes and functions in young and old individuals, but few longitudinal studies in
humans actually delineating changes at the level of the individual. In most studies, the
number and proportion of late-differentiatedT cells, especially CD8+T cells, is reported to
be higher in the elderly than in the young. Limited longitudinal studies suggest that accu-
mulation of these cells is a dynamic process and does indeed represent an age-associated
change. Accumulations of such late-stage cells may contribute to the enhanced systemic
pro-inflammatory milieu commonly seen in older people. We do not know exactly what
causes these observed changes, but an understanding of the possible causes is now
beginning to emerge. A favored hypothesis is that these events are at least partly due to
the effects of the maintenance of essential immune surveillance against persistent viral
infections, notably Cytomegalovirus (CMV), which may exhaust the immune system over
time. It is still a matter of debate as to whether these changes are compensatory and ben-
eficial or pathological and detrimental to the proper functioning of the immune system and
whether they impact longevity. Here, we will review present knowledge of T cell changes
with aging and their relation to chronic viral and possibly other persistent infections.
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INTRODUCTION
Aging affects all physiological systems, of which one of the most
important interacting with and regulating many of the oth-
ers is the immune system. This is composed of multiple cell
types with specifically defined roles within a complex network of
interactions. Immunologists and gerontologists have been inter-
ested in studying the effects of aging on the immune system for
many years (1). Early work suggested that aging changed only
adaptive immunity, but as analytical techniques became more
refined, the innate arm was also found to be subject to age-
related alterations. Nevertheless, T cells still seem to be most
severely affected by aging (2). These changes may lead to clin-
ical consequences such as the increased incidence of infections
and most probably of cancers, cardiovascular diseases, and neu-
rodegeneration in the elderly. However, despite a considerable
amount of experimental work and knowledge we still do not
know what causes these changes with age. Although changes in
the innate immune response have been recently described (3–6)
we will concentrate on changes in the human adaptive immune
response. This review will describe changes in human T cell
phenotypes, functions, and interactions as well as the possible
causes of these changes, focusing on the effects of persistent viral
infection.
IMMUNOSENESCENCE
The aging of the immune system is a dynamic process which may
at least partly reflect adaptation of the response to the evolving
pathogen milieu (7, 8). Not all compartments of the immune
response are aging in the same way, at the same speed or the
same direction (9, 10). There was an assumption that all parts
and functions of the immune system were decreasing with age,
but currently the realization that compensatory increases may be
developing over time is gaining ground. Even previously identi-
fied “senescent” T cells considered as anergic, have been shown to
be able to maintain functions important for mounting effective
immune responses (11, 12). Based on these findings, the ques-
tion is whether these changes are exclusively detrimental or can be
viewed as an adaptation mechanism to the exposures experienced
by the aging organism over the lifetime (8). Better knowledge of
these changes in human aging will also help to design treatments
aimed at restoring appropriate immunity by identifying which
components to manipulate.
The changes occurring in the immune system with aging
are collectively designated “immunosenescence.” This appellation
describes all the changes that occur in all parts of the immune
response with aging, but strictly should be limited only to those
shown to be truly deleterious. Of all the age-associated changes
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identified, those actually known to be deleterious are certainly in
the minority. At the same time, these changes are accompanied by
development of a low grade inflammatory status in many elderly
people (13). Such “inflammaging” is more clearly associated than
cellular changes with syndromes of aging including sarcopenia,
cardiovascular disease, neurodegeneration, and physical frailty. It
would perhaps be more accurate to call the global phenomenon
occurring in the immune system the “Immunopause,” like many
changes in the aging endocrine system, with less overtly negative
implications.
The most noticeable changes are observed in the adaptive
immune system and especially in T cells. T cells are the backbone
of the adaptive immune response. The results of these changes
are relatively well documented in the elderly. They are likely to
be associated with an increased susceptibility to infections but
indirectly possibly also to cancers, autoimmune disorders and
chronic inflammatory diseases. T cell status is monitored primar-
ily by surface marker phenotyping identifying the distribution of
differentiation stages which we extrapolate to predict functional
consequences, some leading to the above-mentioned diseases asso-
ciated with aging. Several lines of experimental evidence suggest
that aging is associated with an increase in memory cells, quan-
titatively more so in the CD8+ compartment but also in the
CD4+ compartment (7, 14). Concomitantly, there is a decrease
of the naïve T cells probably mainly because of the involution of
the thymus with age (15, 16) and the continuous consumption
of existing immunological resources (17) by new and persistent
infections.
How can we phenotypically classify T cells? There are sev-
eral surface markers which can be used. The most important
are the receptors CCR7, CD28, and CD27 and the phosphatase
CD45, which play important roles in T cell activation, prolif-
eration, cytokine production, and lymph node homing. In fine,
the disappearance of these markers from the cell surface may
denotes functional alterations in these T cell properties (7). The
use of these markers of differentiation/exhaustion/memory infla-
tion (18) enables us to identify T cell differentiation stages from
recent thymic emigrant naïve T cells to late-stage TEMRA cells.
These surface markers can be used to distinguish T cell popula-
tions the majority of which will be naïve (N: CCR7+, CD27+++,
CD28+++, CD45RA+), central memory cells (CM: CCR7+,
CD27++, CD28++, CD45RA−), effector memory cells (EM:
CCR7−, CD27±, CD28±, CD45RA−), and terminally differen-
tiated memory cells re-expressing CD45RA (TEMRA: CCR7−,
CD27−, CD28−, CD45RA+). This is currently the most widely
accepted phenotyping model for CD8+ T cells but can be applied
to some extent to CD4+ T cells as well. The memory cells pro-
tect the host from subsequent infections by the same pathogens.
They survive and turn-over homeostatically, driven by IL-7 or IL-
15 (19). Because thymic involution beginning early in life severely
curtails the egress of fresh supplies of naïve cells to the periph-
ery, the diversity and integrity of the T cell repertoire must be
preserved by the homeostatic maintenance of naïve and memory
cells (20).
What does the picture look like in elderly individuals? The
current paradigm is that the more we age (i) the more differ-
entiated/memory T cells are accumulating because of the host’s
immune exposure history (EM and TEMRA cells); (ii) the num-
ber of naïve T cells is decreasing because of thymic involution
and exposure to specific antigen in the periphery; (iii) as there
is a physical limit in the body to the number of circulating cells
the accumulation of memory cells unbalances the naïve/memory
ratio because clonally expanded memory cells are present in larger
numbers than the naïve cells from which they were derived (1,
21) (Figure 1). There is a strong correlation between the chrono-
logical age and the frequency and absolute numbers of TEMRA
CD8+ T cells in most human populations. Moreover, many of
these TEMRA cells can be identified as dysfunctional in terms
of cytokine response to stimulation and mediation of cytotoxic
activity, as well as inability to proliferate. Hence, the accumu-
lated population of late-stage memory cells includes those that
might be senescent in the sense originally used by cell biologists,
i.e., replicative senescence of fibroblasts, defined as permanent cell
cycle arrest after a finite number of cell divisions (1, 22). The
term “immunosenescence” is often confounded with this more
restricted meaning of replicative senescence, especially because
the lack of expression of the costimulatory receptor CD28 by
late-stage CD8+ T cells is associated with essentially post-mitotic
cells. Hence the notion that CD8+CD28− negative cells were
senescent came to be common because of the role of CD28 in
proliferation and functional commitment, in maintaining telom-
erase function, in p38 pathway activation, in modulating apop-
tosis and for adequate cell metabolism (23–25). By analogy to
the replicatively senescent cells of Hayflick’s fibroblast cultures,
those T cells which are not able to proliferate further were also
considered as senescent. However, since these early observations
were made, it has become evident that these differentiated T
cells can under some circumstances regain proliferative capacity,
such as after manipulation of KLRG1 (26, 27). The most likely
explanation to account for the observed accumulation of late-
stage memory cells in older humans is that while many are fully
FIGURE 1 | Phenotypic characterization ofT cells and their changes in
aging. There are four major differentiation stages of T cells characterized by
the presence or absence of different surface markers in this popular model.
With aging the naïve cell compartment is shrinking while the memory is
expanding. There is also a loss of diversity with aging.
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functional, this functionality no longer requires further clonal
expansion of those antigen-specific cells. On the other hand,
the accumulation of very large amounts of CD8+ TEMRA cells
may result in overcrowding (shrinkage of the “immunological
space” for other cells) because at least some of them are genuinely
senescent.
THE CONTRIBUTION OF LONGITUDINAL STUDIES
Swedish longitudinal studies were the first to investigate immune
predictors of survival and death (28). Therefore, most of our
findings concerning the accumulation of late-stage differentiated
CD8+ T cells and whether this results in any negative conse-
quences come from studies such as the OCTO and NONA longitu-
dinal studies (29). These defined an “Immune Risk Profile” (IRP)
as a cluster of parameters characterized by an inverted CD4/CD8
ratio due to an accumulation of CD8+CD28− T cells, associated
with poor proliferative responses to T cell mitogens, but including
low B cell counts and seropositivity for CMV. The IRP was defined
a metric predictive of 2, 4 and 6 year mortality in people 85 years
old at baseline. These findings largely contributed to our under-
standing of the cellular and molecular mechanisms underlying the
decreased immune response with age (30). They characterized for
the first time by TCR clonotype mapping the expansion of spe-
cific CD8+ T cell clones already described in mice and humans
(31, 32). This decreased diversity of the total CD8 repertoire par-
alleled that of CD4 with age (33). Not only is there a decreased
diversity, but these studies confirmed that the CD8 clones were
strongly associated with CMV seropositivity (34), however in a
much larger number of elderly and even older than in all other
previous studies (30). It is now clear that persistent/latent CMV
infection per se is associated with the accumulation of large pop-
ulations of late-stage differentiated CD8+ T cells characterized by
lack of expression of CD28 and acquired expression of the negative
signaling receptor CD57, accompanied by decreased functionality
(35). Moreover, in these Swedish studies it was also shown that the
best predictor for survival was the inverted CD4/CD8 ratio (36)
absent in “successful aging,” as epitomized by centenarians (37).
The role of CMV in this respect was puzzling and to some extent
remains so.
A seminal study by Simanek et al. (38) showed for the first time
in a population of >10,000 adults that CMV positivity together
with higher levels of the inflammatory marker CRP was associ-
ated with significantly poorer survival compared to those who
did not have CMV seropositivity and/or CRP increased level. This
remained the case in this NHANES cohort after correcting for
multiple confounding factors. This suggests that CMV seroposi-
tivity is associated with poorer survival in people with increased
background inflammation levels, borne out by such deaths being
mostly cardiovascular. However, causation was not demonstrated
and involvement of alterations in the immune system not shown
(39). It also needs to be borne in mind that CMV infection per se
has not been associated with increased background inflammation
in all studies (40). Nonetheless, other studies also support the
notion that CMV-seropositive elderly individuals have a higher
propensity to suffer from other age-associated diseases with an
inflammatory component, such as cardiovascular disease and can-
cer (14, 39, 41). Moreover, the IRP could rarely be found in other
healthy populations or even in very ill elderly (42). So the ques-
tion arises whether these changes are related to aging or to the
chronic CMV infection or do they exist as an innocent bystander
amplification?
WHAT MIGHT THEN CAUSE THESE CHANGES IN ADAPTIVE
IMMUNITY WITH AGE?
Recently a new paradigm emerged, mainly following these longitu-
dinal studies, to explain the changes with age in T cell phenotypes
and functions characterized by more and more differentiated
CD4+ and CD8+ T cells: CMV seropositivity determines the
increase of CD8+ TEMRA cells with a large proportion recogniz-
ing CMV antigens (43). It is of note that EBV-specific peripheral T
cells are mainly effector memory phenotype, not so differentiated
as for CMV. In parallel, EBV has not been strongly associated with
immunosenescence and with mortality. Therefore, circumstantial
evidence points to a unique effect of CMV on the accumulation of
CD8+ TEMRA cells, presumably due to chronic antigenic stimu-
lations by the persisting virus. However, this does not exclude the
possibility that other viruses, or other completely different antigen
sources, could have similar effects, for example, in the absence of
CMV infection.
To better understand the eventual contribution of the differ-
ent viruses we should clarify what persistent and chronic viral
infections mean (44). Contrarily to acute viral infections, persis-
tent infections have a longer duration mainly because the viral
source is not cleared by the immune system and usually resides
inside certain cell types (e.g., immune cells, neuronal cells, and
epithelial cells). Persistent infections may involve stages of both
silent and productive infection without rapidly killing or even pro-
ducing excessive damage of the host cells. Varicella-zoster virus,
measles virus, HIV-1, HHS-6, HHS-7, HSV-1, HSV-2, and human
cytomegalovirus (CMV) are examples of viruses that cause typical
persistent infections. Latent infection is characterized by the lack
of demonstrable infectious virus between episodes of recurrent
disease. A latent infection is a phase in certain viruses’ life cycles in
which after initial infection, virus production ceases (HSVs,VZV).
Chronic infection is characterized by the continued presence of
infectious virus following the primary infection and may include
chronic or recurrent disease. A chronic infection is a type of per-
sistent infection that may be eventually cleared such as HBV, while
latent infections such as EBV, CMV, and other herpes viruses per-
sist for the lifetime of the host. Although persistent in nature their
natural histories are completely different (44). It is not known
why CMV has such a unique effect on immunity, or whether it
remains latent in older people. Certainly, CMV reactivates period-
ically in adults, usually asymptomatically and therefore difficult to
identify and study. Little is known about whether reactivation is
more frequent on the elderly, and if so what the consequences are,
if any.
Thus CMV has evolved to avoid elimination by the hosts’
immune effector mechanisms and to persist mostly, presumably,
in a non-replicative latent state (because CMV viremia is rare in
healthy people). There is evidence to suggest that this latency is
nevertheless a highly dynamic condition during which episodes of
viral gene desilencing, which can be viewed as incomplete reacti-
vations, cause intermittent antigenic activity that stimulates CD8
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clonal expansion (8, 45, 46). All the other persistent virus have a
different tissue specificity, reactivation inducers and amounts in
the circulation as antigen resulting in a very different immune
modulating effect compared to CMV (44, 47). We describe and
summarize these differences in Figure 2.
CHRONIC ANTIGENIC STIMULATION
The effect of chronic infection caused by CMV will be specifi-
cally discussed although various other chronic viral infections such
as EBV, hepatitis B virus (HBV), human papilloma virus (HPV),
or HIV (48) can also be considered as sources of chronic stress
(Figure 2). It is well known that these viruses can reactivate when
immunity is suppressed, suggesting that constant immune surveil-
lance is required to prevent their reactivation (49, 50). They induce
responses of virus-specific CD8+ T cells which can be detected
long after the virus is controlled (51). Among these viruses HIV,
inducing a distinct and well characterized viral disease at any age,
was shown to be constantly replicating and causing an antigen-
dependent clonal expansion of the memory T cells somewhat
resembling what is found in the aging immune system (52). This
led to a generalized concept of premature immunosenescence in
HIV patients independent of their age (53). It is of note that basal
viral load is constantly present in these individuals (44). Thus HBV
(54), HIV (52), and CMV (55) are likely to drive the accumulation
of memory T cells at any age, but not EBV and VZV due to their
different life cycle and pathophysiology (47, 56, 57).
In this regard, HIV is very interesting and became important
for the elderly since the success of antiretroviral therapy (ART).
HIV was considered as a premature immunosenescence driver
either for CD4+ or CD8+ T cells which showed certain char-
acteristic surface markers and functions as found in elderly HIV
uninfected people (53, 58). Many subjects suffering from AIDS
now survive to become elderly and thus represent those with a
different chronic viral infection from CMV. A persistent systemic
inflammation characterizes the clinically latent or asymptomatic
stage of the disease under good viral load control by ART (59, 60).
Thus, there is continuous antigen stimulation, ongoing inflam-
matory process and CD4+ T cell loss. The chronological aging of
HIV subjects is thus a good model to contrast with the known
FIGURE 2 | Impact of different chronic viral infections on the immune
system and clinical consequences in young and elderly subjects. The
immunological and clinical impact of these viral infections is different in
young and elderly and even among elderly; however they present a
persistent antigenic stimulation throughout life.
effects of CMV for discovering what is really due to a specific
virus or to general virus-specific processes or to the aging process
itself (53).
In addition to viruses, other stimulating agents may be present.
This is perhaps the case for the continuous emergence of cancer
antigens independent of the overt presence of clinical cancer (61).
Indeed, many cancers such as advanced renal carcinoma, head and
neck cancers, and melanomas are associated with the presence
of late-differentiated CD8+ T cells (62, 63). Moreover, bacter-
ial chronic/latent infections may also contribute; a good example
might be Helicobacter pylori. Furthermore, one important source
of continuous antigenic stimulation is the gut. It is conceivable that
in aging the epithelial surface integrity is disrupted and becomes
leaky to antigens coming directly from nutrients or from the gut
microbiome, as is the case in HIV infection (64). These antigens
can also drive T cells to late differentiation or exhaustion. Further-
more, CD28− CD8+ T cells are found in healthy elderly and in
many disease states either in young or elderly subjects. This sug-
gests that the origin of these cells is related to the disease more
than the chronological age, and could be caused by chronic anti-
genic stimulation such as may occur in Alzheimer’s Disease (AD)
or rheumatoid arthritis (65–67). In fact, we hypothesize that the
increase of late-differentiated CD8+ and CD4+ T cells in AD is
related to the constant presence of amyloid beta peptide. There-
fore, the effects of these chronic antigenic stimulations may be
quite different from that observed during chronic CMV infection.
Thus, why CMV is so special?
CHRONIC CMV STIMULATION
The fraction of the population infected with CMV depends on
socio-economic status, with a prevalence is between 60 and 70%
in industrialized countries, while in emerging countries it is almost
100%. Many studies were also performed in younger groups
and children to confirm the persistence of this infection. It is
of note that CMV may intermittently reactivate during the life-
time and must be maintained in a quiescent state to allow the
remaining immune system to function. That is why the paradigm
that constant antigenic stimulation by CMV induces immunose-
nescence was suggested. Nevertheless, it is of particular impor-
tance in this context that even young children infected with
CMV have similar increased memory CD8+ profiles, decreased
diversity in the naïve pool either and this led to the concept
that CMV infection results in immune senescence at an earlier
age (17, 68, 69). This would suggest that the so-called T cell
senescence is not only age-dependent but CMV-dependent and
what is seen in aging is the same as is observed in young or
middle-aged subjects except that more time has passed since the
initial infection. These findings underscore the general concept
developed above that chronic antigenic stress is responsible for
age-associated changes to the distribution of T cell differentia-
tion phenotypes independent of chronological age, but increas-
ing as age increases due to more extensive pathogen exposures
throughout life.
The price paid by the adaptive immune system to maintain
CMV in a latent phase is very high in terms of resource dedica-
tion (70, 71). In elderly subjects as many as 50% of CD8+ and
30% of CD4+ T cells can be CMV-specific (72) at the expense of
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the naïve and other more highly diversified memory T cells. The
question is whether the remaining T cells are functional or not
and this warrants further investigation. If they are not devoted
to CMV their changes should be related to the aging process
only, although “bystander” effects of the CMV-specific cells are
conceivable too.
Current evidence suggests that CMV infection is a pre-eminent
agent driving the differentiation of the CD8+ T cell compart-
ment with aging (73–75) as has also been shown in mice (45,
76, 77). As mentioned above, most of these CMV-specific CD8+
T cells are of TEMRA phenotype with decreased CD28, CD27,
CCR7, CD62L, and increased CD57 and re-expressed CD45RA
surface markers indicating some putative functional alteration
(52). These include decreased proliferative capacity (78, 79) but
maintenance of markers of lineage commitment, memory, and
cell–cell adhesion. However, even though some may be senescent,
for example in terms of smaller proportions responding to specific
antigen by producing IFN-γ, the absolute number of these cells is
so greatly increased that the overall reactivity is enhanced, not
decreased (80). This is also likely to contribute to the development
of age-associated low grade inflammation and the consequent age-
associated diseases (13, 81, 82). It is of note that this phenomenon
is also seen in HIV-infected patients (53). Perhaps, as with the well-
defined replicatively senescent cells these TEMRA CD8+ T cells
may be largely pro-inflammatory producing a large amount of
IL-6, TNFα, and IL-1β (83). However, more evidence has recently
emerged that CD28-negative T cells are not necessarily (all) termi-
nally differentiated or senescent because using specific costimuli
such as 4-1BBL, OX40L, and cytokine supplementation with IL-2
or IL-15 revealed a retained proliferative capacity (11, 12). As they
proliferate under IL-15 this implies that they are also sensitive
to homeostatic control in vivo and cannot be considered as truly
replicatively senescent (12, 84, 85). Furthermore, these TEMRA
cells express high levels of Bcl-2 and are more apoptosis-resistant
than naïve CD8+ T cells (34). This means that they will continue
to accumulate over a longer period of time (i.e., during aging). The
survival of these cells is energy-consuming. It is clear that in the
competition for nutrients and factors to maintain these “function-
ally” different pro-inflammatory CD8+ T cells, they will largely
outcompete the other T cell subpopulations. They have a survival
advantage, with probably a very strong metabolic advantage too.
Thus, their maintenance from a metabolic/energetic point of view
is very costly and potentially harmful for the survival and func-
tion of other T cell subpopulations. This is further corroborated
by the fact that CMV largely relies on the host’s mTOR pathway
to maintain its viral reactivation potency from its latent form (86,
87). Thus, the presence of these metabolically very active CD8+
T cells may contribute to reactivation of CMV and thus to their
further expansion, creating a vicious circle increasing with age.
Consistent with this, recent evidence highlights and confirms the
suppressive effect of mTOR toward CMV infection (87, 88). Thus,
not only are these cells accumulating, but their maintenance in
the system costs a lot of energy, thus depleting reserves, further
impairing the composition and function of the remaining immune
system.
In summary,apart from the robust Swedish longitudinal studies
involving CMV infection/seropositivity in the so-called IRP, there
is very little data to establish whether and how CMV positivity
can further influence and shape the immune response in elderly
subjects. There is no doubt that CMV is a contributory factor but
certainly not the whole story (73, 74). Further longitudinal and
functional studies are badly needed to establish the relationship
between CMV and aging and mainly the true immunological and
clinical effects of this relationship.
WHAT IS THE SIGNIFICANCE OF THESE CHANGES IN THE
PERSPECTIVE OF AGING?
All these experimental data suggest that the dysregulation of the
immune response or “immunopause” with aging may be due to
a chronic antigen-driven process, especially but most likely not
exclusively due to chronic CMV infection. The involvement of
other factors as well as CMV must of course be recognized, if only
because not all individuals are infected with CMV. Thus, there is a
significant decrease in naïve T cells independent of CMV positivity
even if CMV may further contribute to their decrease (55). CMV-
negative individuals show less differentiated (CM and EM profile
mainly) CD8+ T cells than CMV-positive elderly individuals (EM
and TEMRA mainly) but this is just a question of proportion
and both types are increased and have different functioning in
elderly compared to young subjects. These CD8+ T cell pheno-
typic changes are also present in young CMV-positive individuals
(66, 68), but we have no longitudinal data on the survival and T
cell shifts in these young individuals throughout time. Addition-
ally, the CD4+ compartment is also altered with aging (68, 72)
but here CMV plays as much less prominent role than for CD8+
T cell differentiation.
CLINICAL CONSEQUENCES
The clinical consequences of the altered immune response with
age are quite well-defined even if for most of them we have only
circumstantial evidence. The increased infections, mainly new
infections, indicate that naïve T cells’ functionality and/or diver-
sity is altered also with aging and probably not only because of
expanded CMV-specific T cells. It has been difficult to demon-
strate that elderly have more active CMV infections than young
subjects (89). Our own unpublished study showed that in elderly
subjects suffering from pneumonia, we could not find acute CMV
infection. This means that either the CMV-specific T cells are
very efficient or that aging does not influence their functional-
ity even if their numbers are increasing. It is of note that our
actual clinical measure of CMV reactivation is far from being
accurate.
An important clinical consequence of this increased CMV-
specific CD8+T cell clonally expanded pool with the concomitant
decrease of the naïve T cell diversity is the decreased vaccine
response in elderly (90). Thus, individuals having a large number
of CD28− CD8+ T cells produce much less protective antibody
following influenza vaccination than those having less of these
cells (91). There were no studies on the CMV-specificity of these
cells; nevertheless, regarding earlier studies it was speculated that
CMV-induced CMV-specific CD8+ T cells decrease the response
to influenza vaccine (92). However, in a different study, Saurwein-
Teissl et al. (93) could not demonstrate any specificity of these
CD8+ T cells for CMV, EBV or influenza viruses. The negative
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FIGURE 3 | Schematic conceptualization of the effects of aging on
the immune system. Through the progression of time the immune
reserves are decreasing, the baseline is approaching to the threshold for
inducing an efficient response, the immune response is less vigorous
and maintained due to a complete reshaping of the immune cells by the
immune history, such as persistent viral infection, putatively CMV.↔:
Represents possible CMV infection effects on the immune reserve and
the threshold.
impact of CMV infection on the outcome of influenza vaccina-
tion in elderly people has been explicitly tested more recently and
is seen in many studies [e.g., (94,95)],but not all (96). However, the
latter study in nursing home elderly only considered the antibody
response to one of the three viral strains in that seasonal vac-
cine and found no difference in titers between CMV-infected and
CMV-negative. As the WHO criteria for responsiveness specific
reactions to two or more of the three strains, had this study exam-
ined the other two, a difference may have emerged. It is unclear
why this was not reported.
Furthermore, CMV-infected individuals having expanded
memory T cell populations have been shown to have a higher
risk for coronary heart disease due to vascular inflammation (97,
98) and even for type 2 diabetes (99). Thus, CMV infection can be
involved indirectly in the development of chronic inflammatory
diseases which are increased in aging. Or vice versa the existence
of these inflammatory diseases renders the elderly more suscep-
tible to CMV reactivation. Nevertheless, as already mentioned,
CMV positivity is associated with higher all cause of mortality
than CMV seronegativity.
CONCLUSION
It is well known that aging is associated with increased suscep-
tibility to many diseases due to dysregulated immune responses
(Figure 3). However, we still do not know what the causes of
this dysregulated immune response with aging really are. Here, it
was argued that chronic antigenic stimulation, especially but not
only due to CMV infection, plays a crucial role. However, dis-
secting the effects on immune alterations in elderly individuals
with respect to age, low grade-inflammation, disease and CMV
seropositivity remains a big challenge. We are currently approach-
ing this challenge by assessing individual variations in responses
to CMV, namely antibody titer, specificity, and neutralizing activ-
ity and determination of the specific CMV cell reservoirs (e.g.,
monocytes) rather than just “infected vs. not infected” (100).
This approach appears to us more likely to yield informative
data in populations where almost all subjects are infected with
the virus, for instance elderly individuals even in industrialized
countries and essentially everyone in developing countries. Fur-
thermore, longitudinal studies are needed including young and
elderly healthy individuals to dissect the effects of age vs. CMV
infection. It is also warranted that comparable studies alone or
in combination with other persistent viruses to be carried out
to exactly determine their effects on the aging immune sys-
tem. Finally, we should also consider that CMV infection is not
uniquely a deleterious process but a constant trigger to main-
tain “alertness” in the aged immune system to be able to respond
correctly to known antigens and overcoming the immunopause
by the immunoadaptation triggered and maintained by persis-
tent viral infection (Figure 3). Future experimental studies will
help us to design efficient and intelligent interventions such as
a vaccination or other means (gene silencing, antiviral agents,
tissue-specific cell deletion, anti-inflammatory agents) to reinforce
homeostasis and maintain a holistically adapted immune response
to aging.
ACKNOWLEDGMENTS
This work was supported by grants from the Canadian Insti-
tutes of Health Research (CIHR) (No. 106634 and No. 106701),
the Université de Sherbrooke, the Research Center on Aging,
the European Commission [FP7 259679 “IDEAL”], the Ger-
man Research Foundation [DFG-PA 361/14-1] and, the German
Federal Ministry of Education and Research [BMBF 0315890F,
“Gerontoshield”].
Frontiers in Immunology | T Cell Biology September 2013 | Volume 4 | Article 271 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fülöp et al. Human T cell aging
REFERENCES
1. Effros RB. Telomere/telomerase
dynamics within the human
immune system: effect of
chronic infection and stress.
Exp Gerontol (2011) 46:135–40.
doi:10.1016/j.exger.2010.08.027
2. Linton PJ, Dorshkind K. Age-
related changes in lymphocyte
development and function. Nat
Immunol (2004) 5:133–9. doi:10.
1038/ni1033
3. Agrawal A, Gupta S. Impact of
aging on dendritic cell functions
in humans. Ageing Res Rev (2011)
10:336–45. doi:10.1016/j.arr.2010.
06.004
4. Fülöp T, Fortin C, Lesur O,
Dupuis G, Kotb JR, Lord JM,
et al. The innate immune sys-
tem and aging: what is the
contribution to immunosenes-
cence? Open Longevity Science
(2012) 6:121–32. doi:10.2174/
1876326X01206010121
5. Camous X, Pera A, Solana R, Larbi
A. NK cells in healthy aging and
age-associated diseases. J Biomed
Biotechnol (2012) 2012:195956.
doi:10.1155/2012/195956
6. Daley-Bauer LP, Wynn GM,
Mocarski ES. Cytomegalovirus
impairs antiviral CD8+ T cell
immunity by recruiting inflam-
matory monocytes. Immunity
(2012) 37:122–33. doi:10.1016/j.
immuni.2012.04.014
7. Larbi A, Rymkiewicz P, Asudev A,
Low I, Shadan BN, Mustafah S,
et al. The immune system in the
elderly: a fair fight against dis-
eases. Aging Health (2013) 9:1–13.
doi:10.2217/ahe.12.78
8. Pawelec G. Hallmarks of human
“immunosenescence” adaptation
or dysregulation? Immunol Age-
ing (2012) 9:15. doi:10.1186/1742-
4933-9-15
9. Fülöp T, Le Page A, Garneau H,
Azimi N, Baehl S, Dupuis G, et
al. Aging, immunosenescence and
membrane rafts: the lipid connec-
tion. Longevity Healthspan (2012)
1:6. doi:10.1186/2046-2395-1-6
10. Solana R, Tarazona R, Inmaculada
G, Lesur O, Dupuis G, Fülöp T.
Innate immunosenescence: effect
of aging on cells and recep-
tors of the innate immune sys-
tem in humans. Semin Immunol
(2012) 24:331–41. doi:10.1016/j.
smim.2012.04.008
11. Kober J, Leitner J, Klauserm C,
Woitekm R, Majdicm O, Stöcklm
J, et al. The capacity of the TNF
family members 4-1BBL, OX40L,
CD70, GITRL, CD30L and LIGHT
to costimulate human T cells. Eur J
Immunol (2008) 38:2678–88. doi:
10.1002/eji.200838250
12. Chiu WK, Fann M, Weng NP.
Generation and growth of
CD28nullCD8+ memory T cells
mediated by IL-15 and its induced
cytokines. J Immunol (2006)
177:7802–10.
13. Franceschi C, Bonafè M, Valensin
S, Olivieri F, De Luca M, Ottaviani
E, et al. Inflamm-aging. An evolu-
tionary perspective on immunose-
nescence. Ann N Y Acad Sci
(2000) 908:244–54. doi:10.1111/j.
1749-6632.2000.tb06651.x
14. Le Saux S, Weyand CM, Goronzy
JJ. Mechanisms of immunose-
nescence: lessons from models of
accelerated immune aging. Ann
N Y Acad Sci (2012) 1247:69–82.
doi:10.1111/j.1749-6632.2011.
06297.x
15. Aspinall R, Andrew D. Thymic
involution in aging. J Clin Immunol
(2000) 20:250–6. doi:10.1023/A:
1006611518223
16. Spielmann G, McFarlin BK,
O’Connor DP, Smith PJ, Pircher
H, Simpson RJ. Aerobic fitness
is associated with lower pro-
portions of senescent blood
T-cells in man. Brain Behav
Immun (2011) 25:1521–9.
doi:10.1016/j.bbi.2011.07.226
17. Weinberger B, Lazuardi L,
Weiskirchner I, Keller M, Neuner
C, Fischer KH, et al. Healthy aging
and latent infection with CMV
lead to distinct changes in CD8+
and CD4+ T-cell subsets in the
elderly. Hum Immunol (2007)
68:86–90. doi:10.1016/j.humimm.
2006.10.019
18. Sallusto F, Geginat J, Lanzavec-
chia A. Central memory and
effector memory T cell subsets:
function, generation, and mainte-
nance. Annu Rev Immunol (2004)
22:745–63. doi:10.1146/annurev.
immunol.22.012703.104702
19. Surh CD, Sprent J. Homeosta-
sis of naive and memory T cells.
Immunity (2008) 29:848–62. doi:
10.1016/j.immuni.2008.11.002
20. Nikolich-Zugich J. Ageing and
life-long maintenance of T-cell
subsets in the face of latent
persistent infections. Nat Rev
Immunol (2008) 8:512–22. doi:10.
1038/nri2318
21. Saule P, Trauet J, Dutriez V, Lekeux
V, Dessaint JP, Labalette M. Accu-
mulation of memory T cells from
childhood to old age: central and
effector memory cells in CD4(+)
versus effector memory and termi-
nally differentiated memory cells
in CD8(+) compartment. Mech
Ageing Dev (2006) 127:274–81.
doi:10.1016/j.mad.2005.11.001
22. Hayflick L, Moorhead PS. The
serial cultivation of human diploid
cell strains. Exp Cell Res (1961)
25:585–621. doi:10.1016/0014-
4827(61)90192-6
23. Di Mitri D, Azevedo RI, Henson
SM, Libri V, Riddell NE, Macaulay
R, et al. Reversible senescence in
human CD4+CD45RA+CD27−
memory T cells. J Immunol
(2011) 187:2093–100.
doi:10.4049/jimmunol.1100978
24. Henson SM, Riddell NE, Akbar
AN. Properties of end-stage
human T cells defined by
CD45RA re-expression. Curr
Opin Immunol (2012) 24:476–81.
doi:10.1016/j.coi.2012.04.001
25. Lazuardi L, Herndler-Brandstetter
D, Brunner S, Laschober GT,
Lepperdinger G, Grubeck-
Loebenstein B. Microarray
analysis reveals similarity between
CD8+CD28− T cells from
young and elderly persons, but
not of CD8+CD28+ T cells.
Biogerontology (2009) 10:191–202.
doi:10.1007/s10522-008-9167-1
26. Henson SM, Franzese O, Macaulay
R, Libri V, Azevedo RI, Kiani-
Alikhan S, et al. KLRG1 signal-
ing induces defective Akt (ser473)
phosphorylation and proliferative
dysfunction of highly differenti-
ated CD8+ T cells. Blood (2009)
113:6619–28. doi:10.1182/blood-
2009-01-199588
27. Akbar AN, Henson SM. Are
senescence and exhaustion inter-
twined or unrelated processes that
compromise immunity? Nat Rev
Immunol (2011) 11(4):289–95.
doi:10.1038/nri2959
28. Olsson J, Wikby A, Johansson B,
Löfgren S, Nilsson BO, Ferguson
FG. Age-related change in periph-
eral blood T-lymphocyte sub-
populations and cytomegalovirus
infection in the very old: the
Swedish longitudinal OCTO
immune study. Mech Ageing Dev
(2000) 121:187–201. doi:10.1016/
S0047-6374(00)00210-4
29. Wikby A, Ferguson F, Forsey R,
Thompson J, Strindhall J, Löfgren
S, et al. An immune risk pheno-
type, cognitive impairment, and
survival in very late life: impact of
allostatic load in Swedish octoge-
narian and nonagenarian humans.
J Gerontol A Biol Sci Med Sci (2005)
60:556–65. doi:10.1093/gerona/60.
5.556
30. Hadrup SR, Strindhall J, Køll-
gaard T, Seremet T, Johansson
B, Pawelec G, et al. Longitudinal
studies of clonally expanded CD8
T cells reveal a repertoire shrink-
age predicting mortality and an
increased number of dysfunctional
cytomegalovirus-specific T cells in
the very elderly. J Immunol (2006)
176:2645–53.
31. Posnett DN, Sinha R, Kabak S,
Russo C. Clonal populations of T
cells in normal elderly humans:
the T cell equivalent to “benign
monoclonal gammapathy.” J Exp
Med (1994) 179:609–18. doi:10.
1084/jem.179.2.609
32. Callahan JE, Kappler JW, Mar-
rack P. Unexpected expansions
of CD8-bearing cells in old
mice. J Immunol (1993) 151:
6657–69.
33. Naylor K, Li G, Vallejo AN, Lee
WW, Koetz K, Bryl E, et al. The
influence of age on T cell genera-
tion and TCR diversity. J Immunol
(2005) 174:7446–52.
34. Khan N, Shariff N, Cobbold M,
Bruton R, Ainsworth JA, Sin-
clair AJ, et al. Cytomegalovirus
seropositivity drives the CD8 T cell
repertoire toward greater clonal-
ity in healthy elderly individuals. J
Immunol (2002) 169:1984–92.
35. Appay V, Rowland-Jones SL.
Lessons from the study of T-
cell differentiation in persistent
human virus infection. Semin
Immunol (2004) 16:205–12.
doi:10.1016/j.smim.2004.02.007
36. Wikby A, Nilsson BO, Forsey R,
Thompson J, Strindhall J, Löf-
gren S, et al. The immune risk
phenotype is associated with IL-
6 in the terminal decline stage:
findings from the Swedish NONA
immune longitudinal study of very
late life functioning. Mech Ageing
Dev (2006) 127:695–704. doi:10.
1016/j.mad.2006.04.003
37. Strindhall J, Nilsson BO, Löfgren
S, Ernerudh J, Pawelec G, Johans-
son B, et al. No Immune Risk
Profile among individuals who
reach 100 years of age: findings
from the Swedish NONA immune
longitudinal study. Exp Gerontol
(2007) 42:753–61. doi:10.1016/j.
exger.2007.05.001
38. Simanek AM, Dowd JB, Pawelec
G, Melzer D, Dutta A, Aiello AE.
Seropositivity to cytomegalovirus,
inflammation, all-cause and car-
diovascular disease-related mor-
tality in the United States. PLoS
ONE (2011) 6(2):e16103. doi:10.
1371/journal.pone.0016103
39. Pawelec G, McElhaney JE, Aiello
AE, Derhovanessian E. The impact
of CMV infection on survival in
older humans. Curr Opin Immunol
www.frontiersin.org September 2013 | Volume 4 | Article 271 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fülöp et al. Human T cell aging
(2012) 24:507–11. doi:10.1016/j.
coi.2012.04.002
40. Bartlett DB, Firth CM, Phillips
AC, Moss P, Baylis D, Syddall H,
et al. The age-related increase in
low-grade systemic inflammation
(Inflammaging) is not driven by
cytomegalovirus infection. Aging
Cell (2012) 11:912–5. doi:10.1111/
j.1474-9726.2012.00849.x
41. Vescovini R, Biasini C, Telera AR,
Basaglia M, Stella A, Magalini F, et
al. Intense antiextracellular adap-
tive immune response to human
cytomegalovirus in very old sub-
jects with impaired health and
cognitive and functional status. J
Immunol (2010) 184:3242–9. doi:
10.4049/jimmunol.0902890
42. Plonquet A, Bastuji-Garin S, Tah-
maseb F, Brisacier C, Ledudal K,
Farcet J, et al. Immune risk phe-
notype is associated with nosoco-
mial lung infections in elderly in-
patients. Immun Ageing (2011) 8:8.
doi:10.1186/1742-4933-8-8
43. Sylwester AW, Mitchell BL,
Edgar JB, Taormina C, Pelte C,
Ruchti F, et al. Broadly targeted
human cytomegalovirus-specific
CD4+ and CD8+ T cells dom-
inate the memory compart-
ments of exposed subjects. J
Exp Med (2005) 202:673–85.
doi:10.1084/jem.20050882
44. Boldogh I, Albrecht T, Porter DD.
Persistent Viral Infections. 4th ed.
In: Baron S editor. Medical Micro-
biology. Galveston, TX: University
of Texas Medical Branch at Galve-
ston (1996).
45. Lemmermann NA, Böhm V,
Holtappels R, Reddehase MJ.
In vivo impact of cytomegalovirus
evasion of CD8 T-cell immu-
nity: facts and thoughts
based on murine models.
Virus Res (2011) 157:161–74.
doi:10.1016/j.virusres.2010.09.022
46. Gayoso I, Cantisán S, Cerrato
C, Sánchez-García J, Martin C,
Solana R, et al. Clinical factors
influencing phenotype of HCMV-
specific CD8+ T cells and HCMV-
induced interferon-gamma pro-
duction after allogeneic stem cells
transplantation. Clin Dev Immunol
(2013) 2013:347213. doi:10.1155/
2013/347213
47. Thorley-Lawson DA, Hawkins JB,
Tracy SI, Shapiro M. The patho-
genesis of Epstein–Barr virus per-
sistent infection. Curr Opin Virol
(2013) 3(3):227–32. doi:10.1016/j.
coviro.2013.04.005
48. Brunner S, Herndler-Brandstetter
D, Weinberger B, Grubeck-
Loebenstein B. Persistent viral
infections and immune aging.
Ageing Res Rev (2011) 10:362–9.
doi:10.1016/j.arr.2010.08.003
49. Theiler RN, Farr SL, Karon JM,
Paramsothy P, Viscidi R, Duerr
A, et al. High-risk human papil-
lomavirus reactivation in human
immunodeficiency virus-infected
women: risk factors for cervi-
cal viral shedding. Obstet Gynecol
(2010) 115:1150–8. doi:10.1097/
AOG.0b013e3181e00927
50. Legoff J, Amiel C, Calisonni O,
Fromentin D, Rajoely B, Abuaf
N, et al. Early impairment of
CD8+ T cells immune response
against Epstein-Barr virus (EBV)
antigens associated with high level
of circulating mononuclear EBV
DNA load in HIV infection. J
Clin Immunol (2004) 24:125–34.
doi:10.1023/B:JOCI.0000019777.
75784.6f
51. van der Burg SH, Arens R, Melief
CJ. Immunotherapy for persis-
tent viral infections and asso-
ciated disease. Trends Immunol
(2011) 32:97–103. doi:10.1016/j.it.
2010.12.006
52. Appay V, Dunbar PR, Callan
M, Klenerman P, Gillespie GM,
Papagno L, et al. Memory
CD8+ T cells vary in differen-
tiation phenotype in different
persistent virus infections.
Nat Med (2002) 8:379–85.
doi:10.1038/nm0402-379
53. Deeks SG. HIV infection, inflam-
mation, immunosenescence, and
aging. Annu Rev Med (2011)
62:141–55. doi:10.1146/annurev-
med-042909-093756
54. Gruener NH, Lechner F, Jung MC,
Diepolder H, Gerlach T, Lauer G, et
al. Sustained dysfunction of antivi-
ral CD8+ T lymphocytes after
infection with hepatitis C virus.
J Virol (2001) 75:5550–8. doi:10.
1128/JVI.75.12.5550-5558.2001
55. Almanzar G, Schwaiger S, Jenewein
B, Keller M, Herndler-Brandstetter
D, Würzner R, et al. Long-term
cytomegalovirus infection leads
to significant changes in the
composition of the CD8+ T-cell
repertoire, which may be the basis
for an imbalance in the cytokine
production profile in elderly per-
sons. J Virol (2005) 79:3675–83.
doi:10.1128/JVI.79.6.3675-3683.
2005
56. Derhovanessian E, Maier AB, Beck
R, Jahn G, Hähnel K, Slag-
boom PE, et al. Hallmark features
of immunosenescence are absent
in familial longevity. J Immunol
(2010) 185:4618–24. doi:10.4049/
jimmunol.1001629
57. Derhovanessian E, Maier AB, Häh-
nel K, Beck R, de Craen AJ, Slag-
boom EP, et al. Infection with
cytomegalovirus but not herpes
simplex virus induces the accumu-
lation of late-differentiated CD4+
and CD8+ T-cells in humans. J
Gen Virol (2011) 92:2746–56. doi:
10.1099/vir.0.036004-0
58. Méndez-Lagares G, Díaz L,
Correa-Rocha R, León Leal JA,
Ferrando-Martínez S, Ruiz-
Mateos E, et al. Specific patterns of
CD41-associated immunosenes-
cence in vertically HIV-infected
subjects. Clin Microbiol Infect
(2013) 19(6):558–65. doi:10.1111/
j.1469-0691.2012.03934.x
59. Appay V, Sauce D. Immune
activation and inflamma-
tion in HIV-1 infection:
causes and consequences. J
Pathol (2008) 214:231–41.
doi:10.1002/path.2276
60. Ipp H, Zemlin A. The para-
dox of the immune response
in HIV infection: when inflam-
mation becomes harmful. Clin
Chim Acta (2013) 416:96–9. doi:
10.1016/j.cca.2012.11.025
61. Fulop T, Larbi A, Kotb R, de Ange-
lis F, Pawelec G. Aging, immunity,
and cancer. Discov Med (2011)
11:537–50.
62. Characiejus D, Pasukoniene V,
Kazlauskaite N, Valuckas KP,
Petraitis T, Mauricas M, et al. Pre-
dictive value of CD8highCD57+
lymphocyte subset in interferon
therapy of patients with renal cell
carcinoma. Anticancer Res (2002)
22:3679–83.
63. Tsukishiro T, Donnenberg AD,
Whiteside TL. Rapid turnover of
the CD8(+)CD28(-) T-cell subset
of effector cells in the circulation of
patients with head and neck can-
cer. Cancer Immunol Immunother
(2003) 52:599–607. doi:10.1007/
s00262-003-0395-6
64. Brenchley JM, Price DA, Schacker
TW, Asher TE, Silvestri G, Rao S,
et al. Microbial translocation is a
cause of systemic immune acti-
vation in chronic HIV infection.
Nat Med (2006) 12:1365–71. doi:
10.1038/nm1511
65. Larbi A, Pawelec G, Witkowski
JM, Schipper HM, Derhovaness-
ian E, Goldeck D, et al. Dra-
matic shifts in circulating CD4 but
not CD8 T cell subsets in mild
Alzheimer’s disease. J Alzheimers
Dis (2009) 17:91–103. doi:10.
3233/JAD-2009-1015
66. Buchholz VR, Neuenhahn M,
Busch DH. CD8+ T cell differ-
entiation in the aging immune
system: until the last clone stand-
ing. Curr Opin Immunol (2011) 23:
549–54. doi:10.1016/j.coi.2011.05.
002
67. Carvalheiro H, da Silva JA, Souto-
Carneiro MM. Potential roles for
CD8(+) T cells in rheumatoid
arthritis. Autoimmun Rev (2013)
12:401–9. doi:10.1016/j
68. Chidrawar S, Khan N, Wei W,
McLarnon A, Smith N, Nayak L, et
al. Cytomegalovirus-seropositivity
has a profound influence on
the magnitude of major lym-
phoid subsets within healthy
individuals. Clin Exp Immunol
(2009) 155:423–32. doi:10.1111/j.
1365-2249.2008.03785.x
69. Karrer U, Mekker A, Wanke
K, Tchang V, Haeberli
L. Cytomegalovirus and
immune senescence: culprit
or innocent bystander? Exp
Gerontol (2009) 44:689–94.
doi:10.1016/j.exger.2009.09.003
70. Karrer U, Sierro S, Wagner M, Oxe-
nius A, Hengel H, Koszinowski
UH, et al. Memory inflation: con-
tinuous accumulation of antiviral
CD8+ T cells over time. J Immunol
(2003) 170:2022–9.
71. Snyder CM, Cho KS, Bonnett EL,
van Dommelen S, Shellam GR,
Hill AB. Memory inflation dur-
ing chronic viral infection is main-
tained by continuous production
of short-lived, functional T cells.
Immunity (2008) 29:650–9. doi:10.
1016/j.immuni.2008.07.017
72. Pourgheysari B, Khan N, Best
D, Bruton R, Nayak L, Moss
PA. The cytomegalovirus-specific
CD4+ T-cell response expands
with age and markedly alters the
CD4+ T-cell repertoire. J Virol
(2007) 81:7759–65. doi:10.1128/
JVI.01262-06
73. Wills M, Akbar A, Beswick M,
Bosch JA, Caruso C, Colonna-
Romano G, et al. Report from
the second cytomegalovirus and
immunosenescence workshop.
Immunity & Ageing (2011) 8:10.
doi:10.1186/1742-4933-8-10
74. Solana R, Tarazona R, Aiello AE,
Akbar AN, Appay V, Beswick M, et
al. CMV and Immunosenescence:
from basics to clinics. Immun Age-
ing (2012) 9(1):23. doi:10.1186/
1742-4933-9-23
75. Cantisán S, Torre-Cisneros J, Lara
R, Zarraga S, Montejo M, Solana
R. Impact of cytomegalovirus on
early immunosenescence of CD8+
T lymphocytes after solid organ
transplantation. J Gerontol A Biol
Sci Med Sci (2013) 68:1–5. doi:10.
1093/gerona/gls130
Frontiers in Immunology | T Cell Biology September 2013 | Volume 4 | Article 271 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fülöp et al. Human T cell aging
76. Cicin-Sain L, Brien JD, Uhrlaub JL,
Drabig A, Marandu TF, Nikolich-
Zugich J. Cytomegalovirus infec-
tion impairs immune responses
and accentuates T-cell pool
changes observed in mice with
aging. PLoS Pathog (2012) 8:
e1002849. doi:10.1371/journal.
ppat.1002849
77. Mekker A, Tchang VS, Hae-
berli L, Oxenius A, Trkola
A, Karrer U. Immune senes-
cence: relative contributions
of age and cytomegalovirus
infection. PLoS Pathog (2012)
8:e1002850. doi:10.1371/journal.
ppat.1002850
78. Fletcher JM, Vukmanovic-Stejic
M, Dunne PJ, Birch KE, Cook JE,
Jackson SE,et al. Cytomegalovirus-
specific CD4+ T cells in healthy
carriers are continuously driven to
replicative exhaustion. J Immunol
(2005) 175:8218–25.
79. Waller EC, McKinney N, Hicks
R, Carmichael AJ, Sissons JG,
Wills MR. Differential costimu-
lation through CD137 (4-1BB)
restores proliferation of human
virus-specific “effector memory”
(CD28(-) CD45RA(HI)) CD8(+)
T cells. Blood (2007) 110:4360–6.
doi:10.1182/blood-2007-07-
104604
80. Ouyang Q, Wagner WM, Zheng
W, Wikby A, Remarque EJ, Pawelec
G. Dysfunctional CMV-specific
CD8(+) T cells accumulate in the
elderly. Exp Gerontol (2004) 39:
607–13. doi:10.1016/j.exger.2003.
11.016
81. Chung HY, Cesari M, Anton S,
Marzetti E, Giovannini S, Seo
AY, et al. Molecular inflammation:
underpinnings of aging and age-
related diseases. Ageing Res Rev
(2009) 8:18–30. doi:10.1016/j.arr.
2008.07.002
82. MacAulay R, Akbar AN, Henson
SM. The role of the T cell in age-
related inflammation. Age (Dordr)
(2013) 35(3):563–72. doi:10.1007/
s11357-012-9381-2
83. Campisi J. Aging, cellular senes-
cence, and cancer. Annu Rev
Physiol (2013) 75:685–705.
doi:10.1146/annurev-physiol-
030212-183653
84. Alves NL, Arosa FA, van Lier RA.
IL-21 sustains CD28 expression
on IL-15-activated human naive
CD8+ T cells. J Immunol (2005)
175:755–62.
85. Nguyen H, Weng NP. IL-21 prefer-
entially enhances IL-15-mediated
homeostatic proliferation of
human CD28+ CD8 memory T
cells throughout the adult age
span. J Leukoc Biol (2010) 87:43–9.
doi:10.1189/jlb.0209086
86. Brennan DC, Aguado JM, Potena
L, Jardine AG, Legendre C, Säe-
mann MD, et al. Effect of main-
tenance immunosuppressive drugs
on virus pathobiology: evidence
and potential mechanisms. Rev
Med Virol (2013) 23:97–125. doi:
10.1002/rmv.1733
87. Poglitsch M, Weichhart T, Heck-
ing M, Werzowa J, Katholnig K,
Antlanger M, et al. CMV late
phase-induced mTOR activation
is essential for efficient virus
replication in polarized human
macrophages. Am J Transplant
(2012) 12:1458–68. doi:10.1111/j.
1600-6143.2012.04002.x
88. Xu X, Ye L, Araki K, Ahmed
R. mTOR, linking metabolism
and immunity. Sem Immunol
(2012) 24:429–35. doi:10.1016/j.
smim.2012.12.005
89. Stowe RP, Kozlova EV, Yetman
DL, Walling DM, Goodwin JS,
Glaser R. Chronic herpesvirus
reactivation occurs in aging. Exp
Gerontol (2007) 42:563–70. doi:10.
1016/j.exger.2007.01.005
90. McElhaney JE, Zhou X, Talbot
HK, Soethout E, Bleackley RC,
Granville DJ, et al. The unmet need
in the elderly: how immunose-
nescence, CMV infection, co-
morbidities and frailty are a chal-
lenge for the development of more
effective influenza vaccines. Vac-
cine (2012) 30:2060–7. doi:10.
1016/j.vaccine.2012.01.015
91. Goronzy JJ, Fulbright JW, Crow-
son CS, Poland GA, O’Fallon WM,
Weyand CM. Value of immunolog-
ical markers in predicting respon-
siveness to influenza vaccination
in elderly individuals. J Virol
(2001) 75:12182–7. doi:10.1128/
JVI.75.24.12182-12187.2001
92. Trzonkowski P, Mysliwska J, Szmit
E, Wieckiewicz J, Lukaszuk K,
Brydak LB, et al. Association
between cytomegalovirus infec-
tion, enhanced proinflammatory
response and low level of anti-
hemagglutinins during the anti-
influenza vaccination – an impact
of immunosenescence. Vaccine
(2003) 21:3826–36. doi:10.1016/
S0264-410X(03)00309-8
93. Saurwein-Teissl M, Lung TL, Marx
F, Gschosser C, Asch E, Blasko
I, et al. Lack of antibody pro-
duction following immunization
in old age: association with
CD8(+)CD28(−) T cell clonal
expansions and an imbalance
in the production of Th1 and
Th2 cytokines. J Immunol (2002)
168(11):5893–9.
94. Moro-García MA, Alonso-Arias R,
López-Vázquez A, Suárez-García
FM, Solano-Jaurrieta JJ, Baltar J,
et al. Relationship between func-
tional ability in older people,
immune system status, and inten-
sity of response to CMV. Age
(Dordr) (2012) 34:479–95. doi:10.
1007/s11357-011-9240-6
95. Derhovanessian E, Theeten H,
Hähnel K, Van Damme P, Cools
N, Pawelec G. Cytomegalovirus-
associated accumulation of late-
differentiated CD4 T-cells corre-
lates with poor humoral response
to influenza vaccination. Vaccine
(2013) 31:685–90. doi:10.1016/j.
vaccine.2012.11.041
96. den Elzen WP, Vossen AC, Cools
HJ, Westendorp RG, Kroes AC,
Gussekloo J. Cytomegalovirus
infection and responsiveness to
influenza vaccination in elderly
residents of long-term care
facilities. Vaccine (2011) 29:
4869–74. doi:10.1016/j.vaccine.
2011.03.086
97. Blankenberg S, Rupprecht HJ,
Bickel C, Espinola-Klein C,
Rippin G, Hafner G, et al.
Cytomegalovirus infection
with interleukin-6 response
predicts cardiac mortality in
patients with coronary artery
disease. Circulation (2001) 103:
2915–21. doi:10.1161/01.CIR.103.
24.2915
98. Bentz GL, Yurochko AD. Human
CMV infection of endothelial cells
induces an angiogenic response
through viral binding to EGF
receptor and beta1 and beta3 inte-
grins. Proc Natl Acad Sci U S A
(2008) 105:5531–6. doi:10.1073/
pnas.0800037105
99. Chen S, de Craen AJ, Raz Y, Der-
hovanessian E, Vossen AC, West-
endorp RG, et al. Cytomegalovirus
seropositivity is associated with
glucose regulation in the old-
est old. Results from the Lei-
den 85-plus Study. Immun Ageing
(2012) 9:18. doi:10.1186/1742-
4933-9-18
100. Leng SX, Qu T, Semba RD, Li H,
Yao X, Nilles T, et al. Relationship
between cytomegalovirus (CMV)
IgG serology, detectable CMV
DNA in peripheral monocytes,
and CMV pp65(495-503)-
specific CD8+ T cells in older
adults. Age (Dordr) (2011) 33:
607–14. doi:10.1007/s11357-011-
9205-9
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 08 April 2013; accepted: 27
August 2013; published online: 13 Sep-
tember 2013.
Citation: Fülöp T, Larbi A and Paw-
elec G (2013) Human T cell aging
and the impact of persistent viral
infections. Front. Immunol. 4:271. doi:
10.3389/fimmu.2013.00271
This article was submitted to T Cell Biol-
ogy, a section of the journal Frontiers in
Immunology.
Copyright © 2013 Fülöp, Larbi and Paw-
elec. This is an open-access article distrib-
uted under the terms of the Creative Com-
mons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
www.frontiersin.org September 2013 | Volume 4 | Article 271 | 9
